Skip to main content

Table 3 Radiation equivalent doses in the tumour and normal organs for radioimmunoconjugates in NRG mice with s.c. HNSCC primary xenografts a

From: Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy

  Radiation equivalent dose (Sv/MBq)
Organ [64Cu]Cu-DOTA-panitumumab F(ab´)2 b [177Lu]Lu-DOTA-panitumumab F(ab´)2 c [177Lu]Lu-DOTA-panitumumab F(ab´)2 d Comparison of doses for 177Lu calculated from 64Cu vs. 177Lu biodistribution (BOD)
(P-value)
Heart 0.03 ± 0.01 0.35 ± 0.06 0.32 ± 0.13 n.s.
Lungs 0.05 ± 0.01 0.51 ± 0.05 0.38 ± 0.04 n.s.
Liver 0.10 ± 0.02 1.22 ± 0.13 1.82 ± 0.14 0.03
Spleen 0.04 ± 0.01 0.71 ± 0.20 0.66 ± 0.18 n.s.
Pancreas 0.02 ± 0.01 0.26 ± 0.08 0.16 ± 0.04 n.s.
Stomach 0.03 ± 0.01 0.33 ± 0.03 0.27 ± 0.04 n.s.
Intestines 0.02 ± 0.00 0.31 ± 0.05 0.21 ± 0.05 n.s.
Kidneys 0.07 ± 0.01 0.63 ± 0.09 0.75 ± 0.08 n.s.
Tumour e 0.14 ± 0.03 2.00 ± 0.60 2.50 ± 0.80 n.s.
Whole Body 0.05 ± 0.00 0.26 ± 0.02 0.34 ± 0.02 0.05
  1. aEquivalent doses (D) were calculatd as D = Ãs × S × WR, where Ãs is the time-integrated activity in source organs obtained from BOD studies and S are the Snyder values for mice (Bitar et al., 2007; Xie and Zaidi, 2013) and WR is the radiation weighing factor
  2. bEquivalent doses for [64Cu]Cu-DOTA-panitumumab F(ab´)2
  3. cEquivalent doses for [177Lu]Lu-DOTA-panitumumab F(ab´)2 calculated based on the time-integrated activity for [64Cu]Cu-DOTA-panitumumab F(ab´)2 and using S-values for 177Lu
  4. dEquivalent doses for [177Lu]Lu-DOTA-panitumumab F(ab´)2 calculated based on the time-integrated activity for [177Lu]Lu-DOTA-panitumumab F(ab´)2 and using S-values for 177Lu
  5. eSelf-equivalent doses were estimated using the sphere model in OLINDA/EXM software based on the measured tumour volume for 64Cu or 177Lu